Application | Comment | Organism |
---|---|---|
medicine | glutamate carboxypeptidase II is effective in preclinical models of neurological disorders associated with excessive activation of glutamatergic systems. The study validates the use of hydroxamate-based inhibitors in the treatment of a chronic neurological disorder such as neuropathic pain | Homo sapiens |
Crystallization (Comment) | Organism |
---|---|
X-ray structure of human glutamate carboxypeptidase II in complex with hydroxamate-based inhibitors | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-[(2-(R))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid | - |
Homo sapiens | |
4-[(2-(S))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid | - |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q04609 | - |
- |
Purification (Comment) | Organism |
---|---|
- |
Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | enzyme/hydroxamate complexes reveal an unprecedented binding mode in which the putative P1' glutarate occupies the spacious entrance funnel rather than the conserved glutamate-binding S1' pocket. This unique binding mode provides a mechanistic explanation for the structure-activity relationship data, most notably the lack of enantiospecificity and the tolerance for bulky/hydrophobic functions as substituents of a canonical glutarate moiety | Homo sapiens | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
GCPII | - |
Homo sapiens |
glutamate carboxypeptidase II | - |
Homo sapiens |